(Total Views: 318)
Posted On: 09/15/2017 12:34:12 AM
Post# of 72446
My guess is that after Leo requested the interim analysis, the CRO cautioned him on possible investigator bias.
Leo has an idea of how the early patients are doing from the patient reports (placebo didn't show any activity at week 6 in Phase 2a). If they look good, the last thing Leo wants is to jeapodize the trial and more importantly, jeapodize any chance for a deal.
Leo has stated that his priority is partnership. His job isn't to please traders to flip on the interim result. Clinical trial is dynamic and changes can happen at any time.
Leo has an idea of how the early patients are doing from the patient reports (placebo didn't show any activity at week 6 in Phase 2a). If they look good, the last thing Leo wants is to jeapodize the trial and more importantly, jeapodize any chance for a deal.
Leo has stated that his priority is partnership. His job isn't to please traders to flip on the interim result. Clinical trial is dynamic and changes can happen at any time.
(2)
(0)
